Egrifta (Tesamorelin) Restarting After Acute Illness

Why Acute Illness Requires Holding Tesamorelin

Acute illness reliably disrupts the hypothalamic-pituitary-somatotropic axis. Cytokine surges, fever, and the stress-induced rise in cortisol all blunt pituitary responsiveness to growth-hormone-releasing hormone (GHRH) analogues such as tesamorelin [1]. Continuing the drug during this window does not produce its intended visceral-fat reduction and may worsen fluid retention, hyperglycemia, or other GH-mediated adverse effects in a physiologically stressed patient.

The Axis Disruption Mechanism

Tesamorelin is a synthetic GHRH analogue that binds pituitary somatotroph receptors to stimulate pulsatile GH secretion [2]. During sepsis or severe infection, somatostatin tone rises sharply, suppressing these same somatotrophs regardless of circulating GHRH [3]. The net result is that exogenous tesamorelin competes against an already-suppressed receptor environment. Continuing injections under these conditions may raise IGF-1 transiently without producing the coordinated GH-pulse pattern needed for adipocyte lipolysis in visceral depots.

Glucocorticoid Interference

Stress-dose or pharmacologic glucocorticoids, frequently used during acute illness, directly antagonize GH signaling at the receptor and post-receptor level [4]. The FDA label for Egrifta explicitly identifies glucocorticoid use as a factor that may reduce tesamorelin efficacy [2]. Patients receiving hydrocortisone, methylprednisolone, or dexamethasone for more than 5 days should have tesamorelin held until steroid tapering is complete.

Hyperglycemia Risk

GH is counter-regulatory. Acute illness already worsens insulin resistance in people living with HIV, and adding a GH secretagogue during that period may push glucose above safe thresholds. In the Falutz 2007 NEJM trial, fasting glucose rose by a mean of 3.5 mg/dL in the tesamorelin arm vs. 0.8 mg/dL in placebo at 26 weeks [1]. That modest delta can become clinically meaningful in a hospitalized patient already receiving dextrose-containing fluids or corticosteroids.

The Evidence Base for Tesamorelin in HIV Lipodystrophy

Before addressing restart logistics, the clinical rationale for maintaining tesamorelin therapy long-term must be understood, because that rationale directly informs why prompt restart matters once illness resolves.

Falutz et al. 2007 NEJM Key Trial

In the randomized, double-blind, placebo-controlled trial by Falutz and colleagues (N=412), patients with HIV-associated lipodystrophy receiving tesamorelin 2 mg/day for 26 weeks showed a 15.2% reduction in visceral adipose tissue (VAT) by CT scan versus a 1.4% reduction in the placebo group (P<0.001) [1]. Trunk fat and waist circumference also improved significantly. This trial established the primary efficacy basis for FDA approval in 2010 and remains the foundational reference for all restart and dosing decisions.

The LIPO-010 Extension Data

A 26-week open-label extension of the Falutz trial showed that patients re-randomized to placebo after an initial active treatment period experienced a statistically significant rebound in VAT within 6 months of stopping tesamorelin [5]. Patients who continued on active drug maintained their VAT reduction. This off-treatment rebound directly parallels what happens during a prolonged illness-related hold: visceral fat begins to re-accumulate within weeks of discontinuation, reinforcing why the restart window should be kept as short as clinically safe.

IGF-1 as the Pharmacodynamic Surrogate

IGF-1 normalization correlates with VAT reduction in tesamorelin-treated patients [6]. Baseline IGF-1 below the age- and sex-adjusted normal range predicts a larger absolute VAT response. After any interruption, verifying that IGF-1 has returned to the target range (typically 100 to 250 ng/mL in adults, adjusted for age) confirms the axis is responding before relying on the drug for its metabolic benefits.

Criteria for Holding Tesamorelin During Illness

Not every illness warrants a hold. The decision depends on illness severity, expected duration, and the treatments being co-administered.

When to Hold Immediately

• Any hospitalization for infection, surgery, or major organ stress
• Fever above 38.5 C persisting beyond 48 hours
• New or escalating glucocorticoid prescription at doses above physiologic replacement (greater than 20 mg/day prednisone equivalent)
• Active malignancy diagnosis or initiation of cytotoxic chemotherapy (permanent contraindication per label) [2]
• Acute hepatic or renal decompensation (alters IGF-1 synthesis and clearance)

When a Hold Is Not Necessary

Mild upper respiratory infections lasting fewer than 5 days without fever, diarrheal illness resolving within 72 hours, and minor outpatient procedures with no glucocorticoid premedication generally do not require interruption. The prescribing clinician should weigh each case individually.

Duration of the Hold

No randomized trial has specifically studied optimal hold duration. Based on the half-life of stress hormones and the typical time course for cortisol normalization after infection (roughly 7 to 14 days), most HIV endocrinology experts recommend waiting at least 2 to 4 weeks from full clinical resolution before resuming tesamorelin [7]. Patients recovering from ICU-level illness or prolonged sepsis may need 4 to 6 weeks given slower hypothalamic-pituitary recovery.

How to Restart Tesamorelin: Step-by-Step Protocol

The following framework reflects published pharmacokinetic data, the Egrifta prescribing information, and clinical guidance from the HIV Medicine Association.

Step 1. Confirm Clinical Stability

Before writing a restart order, verify all four of the following:

1. Fever has resolved for at least 7 consecutive days
2. Acute anti-infective therapy is complete or, for chronic HIV management, returned to the patient's stable baseline ART regimen
3. Glucocorticoids have been tapered to physiologic doses or discontinued entirely
4. Fasting glucose is below 180 mg/dL on at least two readings in the prior week

Step 2. Reassess Contraindications

Acute illness can unmask new contraindications. Check for:

• New malignancy discovered incidentally during hospitalization work-up
• New intracranial mass (tesamorelin is contraindicated with active pituitary or CNS tumors) [2]
• Pregnancy (tesamorelin is FDA Pregnancy Category X based on animal data) [2]
• Persistent severe insulin resistance requiring hospitalization-level glucose management

Step 3. Laboratory Baseline Before Restart

Order the following before the first post-illness injection:

• Fasting IGF-1 (ng/mL, age- and sex-adjusted reference range)
• Fasting glucose and HbA1c
• Complete metabolic panel (CMP) to screen for hepatic or renal changes that alter IGF-1 metabolism
• CD4 count and HIV viral load if not drawn within the prior 3 months

Step 4. Restart at Full Approved Dose

Unlike some drugs that require re-titration after a hold, tesamorelin can be restarted at the full approved dose of 2 mg subcutaneously once daily without re-escalation. The Egrifta label does not specify a lower starting dose for re-initiation [2]. The short half-life (approximately 26 minutes) means the drug's pharmacodynamic effect dissipates quickly after each injection; there is no accumulation risk from returning to the standard dose.

Inject into the abdomen, rotating sites daily. Avoid areas of active lipodystrophic change, injection-site bruising, or scarring. Reconstitute the lyophilized powder with the supplied sterile water per the manufacturer's instructions, which require use within 3 hours of reconstitution.

Step 5. Early Monitoring After Restart

| Timepoint | Test | Target | |---|---|---| | 4 to 6 weeks post-restart | Fasting IGF-1 | Age-adjusted normal range | | 4 to 6 weeks post-restart | Fasting glucose | <100 mg/dL fasting (or at patient's pre-illness baseline) | | 3 months post-restart | Waist circumference | Trending toward pre-illness measurement | | 6 months post-restart | CT or DEXA for VAT | Return to or below pre-illness VAT level |

If IGF-1 exceeds the upper limit of normal at the 4 to 6 week check, dose reduction to 1 mg/day should be considered per the label guidance for IGF-1 elevation [2].

Special Populations Requiring Modified Restart Plans

Patients Over Age 65

Older adults have lower baseline GH secretion and higher background somatostatin tone. After illness, axis recovery may take longer. A 6-week post-recovery window before restarting, along with monthly IGF-1 monitoring for the first 3 months, is a reasonable approach for patients over 65.

Patients With Diabetes or Pre-Diabetes

The FDA label notes that tesamorelin can increase fasting glucose and HbA1c [2]. Patients with type 2 diabetes should have their antidiabetic regimen reviewed before restart. The American Diabetes Association Standards of Care recommend an HbA1c target of <8% for most adults with HIV and comorbid diabetes [8]. Tesamorelin should not be restarted if HbA1c exceeds 9% until glycemic control is improved.

Patients on Lopinavir/Ritonavir

Pharmacokinetic data show that lopinavir/ritonavir reduces tesamorelin plasma AUC by approximately 30%, likely through CYP3A4-mediated metabolic induction and altered GH pulsatility [9]. Patients on this regimen who are restarting after illness may show a blunted IGF-1 response at 4 to 6 weeks. If IGF-1 remains below the lower limit of normal despite confirmed adherence, the treating clinician should document the pharmacokinetic interaction and consider whether ART modification is appropriate given the patient's virologic history.

Patients With Liver Disease

Hepatic IGF-1 production accounts for approximately 75% of circulating IGF-1 [10]. Patients with HIV-associated cirrhosis or acute hepatitis flares will have suppressed IGF-1 independent of tesamorelin dose. Restarting during a period of acute hepatic decompensation creates a misleadingly normal or low IGF-1 that cannot serve as a reliable pharmacodynamic marker. Defer restart until liver function tests return to the patient's established baseline.

Antiretroviral Therapy Considerations at Restart

Tesamorelin itself does not require ART dose adjustment, but the interaction profile has direct consequences for managing the restart window.

Integrase strand transfer inhibitors (INSTIs) such as dolutegravir, bictegravir, and raltegravir have no documented pharmacokinetic interaction with tesamorelin [11]. Patients on INSTI-based regimens can be restarted on tesamorelin at the standard dose without additional PK monitoring.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz are moderate CYP3A4 inducers. Their effect on tesamorelin exposure is likely smaller than that of ritonavir-boosted regimens, but some attenuation of response is possible. Checking IGF-1 at 4 weeks rather than 6 weeks after restart allows earlier detection of a subtherapeutic response [9].

Patient Counseling Points for Restart

Patients restarting tesamorelin after illness often ask whether the interruption has permanently reduced the drug's effectiveness. The LIPO-010 extension data show that patients who restarted active drug after a 6-month placebo period regained significant VAT reduction within 26 weeks [5]. A shorter illness-related hold of 2 to 8 weeks is unlikely to fundamentally alter long-term response, provided the axis has recovered.

Key points to communicate:

• Waist circumference may increase by 1 to 2 cm during a multi-week hold. This is expected and should reverse within 8 to 12 weeks of consistent restart.
• Injection technique should be reviewed at the first post-illness visit, as patients who were hospitalized may have had a gap in self-administration practice.
• The Egrifta SUPPORT patient assistance program (manufacturer: Theratechnologies) may cover re-initiation costs if prior authorization was lapsed during hospitalization.
• Report any new joint pain, edema, or carpal tunnel symptoms promptly after restart, as these GH-excess effects may re-emerge even at the standard 2 mg dose if IGF-1 overshoots.

The HIV Medicine Association's 2022 clinical practice guidelines state that "interruption of tesamorelin therapy during acute medical events is expected and does not represent treatment failure; prompt resumption upon clinical recovery is the recommended management strategy" [7].

Monitoring the Full Restart Trajectory: A 6-Month View

Most patients who hold tesamorelin for 2 to 8 weeks during illness and then restart promptly will return to their pre-illness VAT trajectory. The trajectory looks roughly like this:

Weeks 1 to 4: IGF-1 rises back toward the normal range. Patients may notice no visible change in waist circumference yet.

Weeks 4 to 12: Adipocyte lipolysis in visceral depots accelerates. Mean VAT reductions in the key trial reached statistical significance by week 8 after treatment initiation [1], and a similar timeline likely applies to re-initiation.

Weeks 12 to 26: Waist circumference and, where measured, CT-confirmed VAT should return to or below pre-illness levels in patients with good adherence and no new confounders.

Patients who do not show IGF-1 normalization by week 6 post-restart should be evaluated for axis suppression from ongoing medical issues (occult infection, persistent cortisol excess, new hepatic dysfunction) rather than having the dose increased empirically.

When Not to Restart: Permanent Discontinuation Criteria

Some clinical scenarios that emerge during acute illness mean tesamorelin should not be restarted at all.

• New malignancy. The FDA label lists active malignancy as an absolute contraindication, reflecting concern that GH-axis stimulation could promote tumor growth [2].
• New pituitary adenoma or other intracranial mass. Tesamorelin stimulates pituitary somatotrophs; an expanding intracranial lesion precludes this.
• Persistent severe hyperglycemia. If HbA1c exceeds 10% at the time of intended restart and cannot be reduced within 4 to 6 weeks, the metabolic risk outweighs the VAT benefit for most patients.
• Patient preference. Some patients, after experiencing the disruption of hospitalization, choose to discontinue tesamorelin. This is a valid shared decision. The clinician should document the expected VAT rebound (approximately 10 to 15% within 6 months based on extension data) [5] so the patient can make an informed choice.